The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine

European Journal of Clinical Pharmacology
D M PierceR A Franklin

Abstract

Five poor metabolisers (PM) and seven extensive metabolisers (EM), of debrisoquine, all healthy volunteers, received 50 mg indoramin orally following an overnight fast. Plasma concentrations of indoramin and 6-hydroxyindoramin were determined by HPLC with fluorimetric detection. In PM subjects, mean values of Cmax (158 ng/ml) and AUC(0-24) (2556 ng X h X m-1) for indoramin were substantially elevated and t 1/2 beta (18.5 h) prolonged by comparison with values in the EM subjects (21.6 ng/ml, 151 ng X h X ml-1 and 5.2 h respectively). For 6-hydroxyindoramin, on the other hand, Cmax (12.4 ng/ml) and AUC (0-8) (47.5 ng X h X ml-1) in PM subjects were significantly lower than in the EM subjects (28.2 ng/ml and 94.7 ng X h X ml-1). There was a tendency to a higher incidence of side-effects in the PM group. Although the difference did not achieve statistical significance (0.1 greater than p greater than 0.05), all the PM subjects experienced sedation compared to only two in the EM group. Differences in blood pressure and pulse rate between the two groups were small. It is concluded that the oxidative metabolism of indoramin is subject to genetic polymorphism, which is probably under the control of the same gene locus as that influenci...Continue Reading

References

Sep 17, 1977·Lancet·A MahgoubR L Smith
Jan 1, 1979·Drug Metabolism Reviews·J R Idle, R L Smith
Jan 1, 1984·European Journal of Clinical Pharmacology·H M NorburyS J Warrington
Jan 1, 1983·European Journal of Clinical Pharmacology·H M NorburyS J Warrington
Dec 1, 1983·Clinical Pharmacology and Therapeutics·M S LennardH F Woods
Jan 1, 1983·European Journal of Clinical Pharmacology·R A FranklinD Stevenson
Jul 1, 1982·Clinical Pharmacology and Therapeutics·N S OatesR L Smith
Jan 1, 1982·Current Medical Research and Opinion·G N VolansT Frost
Mar 1, 1981·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·R A FranklinT Ward
Feb 1, 1980·European Journal of Clinical Pharmacology·L BertilssonH U Schulz

❮ Previous
Next ❯

Citations

Mar 1, 1988·Biopharmaceutics & Drug Disposition·D M PierceR A Franklin
Jan 1, 1989·European Journal of Clinical Pharmacology·K Brøsen, L F Gram
Apr 1, 1997·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·M J de GrootN P Vermeulen
Dec 1, 1990·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·D M Pierce
Jan 1, 1988·European Journal of Clinical Pharmacology·D M PierceR A Franklin
Sep 5, 2002·British Journal of Clinical Pharmacology·Rashmi R Shah
Feb 6, 2004·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Rashmi R Shah
Jan 1, 1991·Fundamental & Clinical Pharmacology·G Alván
Jan 1, 1995·Drug Metabolism Reviews·M Spatzenegger, W Jaeger
Feb 1, 1993·Pharmacology & Therapeutics·A K DalyJ R Idle

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Epigenetics Insights from Twin Studies

Find the latest research on epigenetics and twin studies here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Regulation of Vocal-Motor Plasticity

Dopaminergic projections to the basal ganglia and nucleus accumbens shape the learning and plasticity of motivated behaviors across species including the regulation of vocal-motor plasticity and performance in songbirds. Discover the latest research on the regulation of vocal-motor plasticity here.

Myocardial Stunning

Myocardial stunning is a mechanical dysfunction that persists after reperfusion of previously ischemic tissue in the absence of irreversible damage including myocardial necrosis. Here is the latest research.

Related Papers

British Journal of Clinical Pharmacology
I SchabortD M Pierce
Drug and Therapeutics Bulletin
© 2021 Meta ULC. All rights reserved